EP1438043A2 - Method of reducing type 2 diabetes in high risk patients - Google Patents
Method of reducing type 2 diabetes in high risk patientsInfo
- Publication number
- EP1438043A2 EP1438043A2 EP02790295A EP02790295A EP1438043A2 EP 1438043 A2 EP1438043 A2 EP 1438043A2 EP 02790295 A EP02790295 A EP 02790295A EP 02790295 A EP02790295 A EP 02790295A EP 1438043 A2 EP1438043 A2 EP 1438043A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- diabetes
- converting enzyme
- angiotensin converting
- enzyme inhibitor
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of time to prevent the development of diabetes in such patients; to a method of slowing or reversing the decline of ⁇ -cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of ⁇ -cell function in such individual; a method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual; a method of increasing pancreatic ⁇ -cell perfusion in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for ' a sufficient period of time to increase pancreatic ⁇ -cell perfusion in such individual and a method of lowering aldosterone secretion and renal
- the present invention further relates to the use of an angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of ⁇ -cell function; for increasing islet blood flow; for increasing pancreatic ⁇ -cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.
- ACE angiotensin converting enzyme
- ACE inhibitors are well known in the art for their activity in inhibiting angiotensin converting enzyme, thereby blocking conversion of the decapeptide angiotensin I to angiotensin II.
- the principal pharmacological and clinical effects of ACE inhibitors arise from suppression of synthesis of angiotensin II.
- Angiotensin II is a potent pressor substance and, therefore, blood pressure lowering can result from inhibition of its biosynthesis, especially in animals and humans whose hypertension is angiotensin II related.
- ACE inhibitors are effective antihypertensive agents in a variety of animal models and are clinically useful for the treatment of hypertension in humans.
- ACE inhibitors are also employed for the treatment of heart conditions such as congestive heart failure.
- ACE inhibitors are also useful for the prevention of diabetes in patients that are at high risk for developing diabetes.
- the present invention relates to a method of reducing diabetes in patients who are at risk for developing diabetes comprising administering to such patients an effective amount of an angiotensin converting enzyme (ACE) inhibitor for sufficient period of time to prevent the development of diabetes in such patients; to a method of slowing or reversing the decline of ⁇ -cell function in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to prevent the decline of ⁇ -cell function in such individual; a method of increasing islet blood flow in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase islet blood flow in such individual; a method of increasing pancreatic ⁇ -cell perfusion in an individual comprising administering to an individual an effective amount of an angiotensin converting enzyme inhibitor for a sufficient period of time to increase pancreatic ⁇ -cell perfusion in such individual and a method of lowering aldosterone secretion and renal potassium
- the present invention further relates to the use of an angiotensin converting enzyme (ACE) inhibitor or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of ⁇ -cell function; for increasing islet blood flow; for increasing pancreatic ⁇ -cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.
- ACE angiotensin converting enzyme
- Type 2 diabetes is an important and common risk factor for the development of coronary artery disease, strokes, peripheral arterial disease, and renal and eye disease.
- the direct and indirect costs of diabetes and its complications exceeds $100 billion per year.
- This health and economic impact of diabetes is bound to increase, as the global prevalence of diabetes rises from 4.2% to 5.4% by the year 2025.
- diabetes as used herein includes both type I diabetes, also known as insulin-dependent, diabetes mellitus (IDMM), and type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM).
- IDMM insulin-dependent, diabetes mellitus
- NIDDM non-insulin-dependent diabetes mellitus
- ACE inhibitor angiotensin converting enzyme inhibitor
- Angiotensin I physiologically inactive decapeptide form of angiotensin
- Angiotensin II vasoconstrictive octapeptide form of angiotensin
- Example of ACE inhibitors suitable for use herein are for instance the following compounds: AB-103, ancovenin, benazeprilat, BRL-36378, BW-A575C, CGS- 13928C, CL242817, CV-5975, Equaten, EU-4865, EU-4867, EU-5476, foroxymithine, FPL 66564, FR-900456, Hoe-065, I5B2, indolapril, ketomethylureas, KRI-1177, KRI-1230, L681176, libenzapril, MCD, MDL-27088, MDL-27467A, moveltipril, MS-41 , nicotianamine, pentopril, phenacein, pivopril, rentiapril, RG-5975; RG-6134, RG-6207, RGH0399, ROO-911 , RS-10085-197/RS-2039, RS 5139, RS 86127, RU
- a group of ACE inhibitors of high interest are alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril.
- ACE inhibitor ramipril Pharmaceutically acceptable derivatives of ACE inhibitors are understood to include physiologically tolerable salts of ACE inhibitors, such physiologically tolerable salts are understood as meaning both their organic and inorganic salts, such as are described in Remington's Pharmaceutical Sciences (17th Edition, page 1418 (1985)).
- acidic groups inter alia, sodium, potassium, calcium and ammonium salts are preferred; for basic groups, inter alia, salts of hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, such as, for example, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p- toluenesulfonic acid are preferred.
- basic groups inter alia, salts of hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, such as, for example, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p- toluenesulfonic acid are preferred.
- ACE inhibitors suitable for use herein or their pharmaceutically acceptable derivatives can be used in animals, preferably in mammals, and in particular in human, as pharmaceuticals per se, in mixtures with one another or in the form of pharmaceutical preparations.
- the present invention also relates to pharmaceutical formulations comprising as active ingredient at least one ACE inhibitor and/or an pharmaceutically acceptable derivative thereof in addition to customary pharmaceutically innocuous excipients and auxiliaries and their use in the prevention of diabetes or the decline of ⁇ -cell function, the increasing of islet blood flow or pancreatic ⁇ -cell perfusion and lowering aldosterone secretion and renal potassium wasting and the production of medicaments therefor.
- the pharmaceutical preparations normally contain 0.1 to 99 percent by weight, preferably 0.5 to 95 percent by weight, of the ACE inhibitor and/or an pharmaceutically acceptable derivative thereof.
- the pharmaceutical preparations can be prepared in a manner known per se.
- the ACE inhibitor and/or an pharmaceutically acceptable derivative thereof are brought, together with one or more solid or liquid pharmaceutical excipients and/or auxiliaries and, if desired, in combination with other pharmaceutical active compounds into a suitable administration form or dose form, which can then be used as a pharmaceutical in human medicine or veterinary medicine.
- compositions which contain an ACE inhibitor and/or an pharmaceutically acceptable derivative thereof can be administered orally, parenterally, intravenously, rectally or by inhalation, the preferred administration being dependent on the particular symptoms of the disorder.
- the ACE inhibitors and/or an pharmaceutically acceptable derivative thereof can be used here on their own or together with pharmaceutical auxiliaries, namely both in veterinary and in human medicine.
- auxiliaries which are suitable for the desired pharmaceutical formulation.
- auxiliaries which are suitable for the desired pharmaceutical formulation.
- solvents for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers or colorants.
- the active compounds are mixed with the additives suitable therefor, such as excipients, stabilizers or inert diluents and are brought by means of the customary methods into the suitable administration forms, such as tablets, coated tablets, hard capsules, aqueous, alcoholic or oily solutions.
- suitable administration forms such as tablets, coated tablets, hard capsules, aqueous, alcoholic or oily solutions.
- Inert- excipients which can be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, in particular corn starch. Preparation can take place here both as dry and as moist granules.
- Possible oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil or codliver oil.
- the active compounds are brought into solution, suspension or emulsion, if desired with the substances customary therefor such as solubilizers, emulsifiers or other auxiliaries.
- Suitable solvents for example, are: water, physiological saline solution or alcohols, e.g. ethanol, propanol, glycerol, and additionally also sugar solutions such as glucose or mannitol solutions, or alternatively a mixture of the various solvents mentioned.
- compositions suitable for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active compound of the formula I in a pharmaceutically acceptable solvent, such as, in particular, ethanol or water, or a mixture of such solvents. If required, the formulation can also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers, and also a propellant.
- a pharmaceutically acceptable solvent such as, in particular, ethanol or water, or a mixture of such solvents.
- the formulation can also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers, and also a propellant.
- Such a preparation customarily contains the active compound in a concentration from approximately 0.1 to 10, in particular from approximately 0.3 to 3, % by weight.
- the dose of the active compound to be administered and the frequency of administration will depend on the potency and duration of action of the compounds used; additionally also on the nature of the indication and on the sex, age, weight and individual responsiveness of the mammal to be treated.
- the daily dose in a patient weighing approximately 75 kg is at least 0.001 mg/kg, preferably 0.01 mg/kg, to about 20 mg/kg, preferably 1 mg/kg, of body weight.
- the ACE inhibitors and/or an pharmaceutically acceptable derivative thereof cafi also be used to achieve an advantageous theraupeutic action together with other pharmacologically active compounds for the prevention of the abovementioned syndromes.
- Hemoglobin A ⁇ c (HbA ⁇ c ) levels and medications used - among those diagnosed as having diabetes were also recorded.
- the HbAic levels ⁇ were determined locally. Values higher than 110% of the upper limit of normal for each laboratory were considered to be biochemical confirmation of diabetes.
- the proportion of patients taking study ramipril or open label ACE-inhibitors in the active group was 98.3% at 2 years and 89.7% at 4 years.
- the proportion taking open label ACE-inhibitors in the control group was 11.6% and 21.4% respectively New Diagnosis of Diabetes
- RR indicates relative risk
- Cl confidence interval
- MA microalbuminuria
- ON overt nephropathy
- ULN upper limits of normal
- primary event death, myocardial infarction, or stroke, t Controlling for primary events and development of MA or ON, new diabetes with glycated hemoglobin ⁇ 110 % had a 0.67 RR (95 % Cl, 0.52-0.86).
- TABLE 3 demonstrates the results among subgroups of patients with different risk factors for developing diabetes.
- the results are consistent among those with a waist to hip ratio below or above the median of 0.93 or less or higher than 0.93 and consistent among those with a body mass index (BMI) of 27.7 or less or higher than 27.7, those with or without a history of hypertension, those receiving or not receiving ⁇ -blockers or diuretics at randomization.
- BMI body mass index
- a higher proportion of individuals without diabetes who were randomized to the placebo group than those randomized to the ramipril group received diuretics or ⁇ -blockers (drugs that are associated with glucose intolerance or diabetes) during the study.
- the RR for diabetes in the subgroup of individuals who never took these drugs during the study was consistent with the overall results (RR, 0.62; 95% Cl, 0.43-0.90).
- Body mass index > 27.7 Kg/m 2 1095 63 (5.8) 1146 94 (8.2)
- ACE inhibitors may increase islet blood flow and pancreatic ⁇ -cell perfusion by reducing angiotensin-2 mediated vasoconstriction in the pancreas (Diabetologica. 1998; 41127-133). These effects may potentially slow or reverse the decline in ⁇ -cell function.
- ACE inhibitors may reduce insulin resistance in skeletal muscles (, increase insulin- mediated glucose disposal thereby decreasing the need for pancreatic insulin secretion.
- the increased insulin mediated glucose uptake by skeletal muscle in response to an ACE inhibitor is due to increased bradykinin-mediated nitric oxide production and not to reductions in angiotensin 2 production or action (Am J Physiol. 1999; 277:R332-R336; Br J Clin Pharmacol 1998; 46: 467-471 ).
- agents that increase nitric oxide may also increase insulin-mediated glucose uptake, which include that (1) both insulin-mediated vasodiiation and skeletal muscle glucose metabolism are reduced in obese persons who do not have diabetes (i.e., individuals at risk for diabetes) and in individuals with type 2 diabetes, (2) inhibition of nitric oxide production reproduces this effect in lean individuals, and (3) the effect on insulin sensitivity is greater than can be accounted for by just increased skeletal muscle blood flow (Am J Cardiol. 1999, 84: 25J-27J). ACE inhibitors may also reduce insulin resistance at the liver and fat cell, which would reduced hepatic glucose production and lower free fatty acid levels (Diabetolologia, 1991 ; 34:119-125).
- Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied. Objective: To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among high-risk persons.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34449501P | 2001-10-17 | 2001-10-17 | |
US344495P | 2001-10-17 | ||
PCT/EP2002/011636 WO2003032963A2 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1438043A2 true EP1438043A2 (en) | 2004-07-21 |
Family
ID=23350759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02790295A Withdrawn EP1438043A2 (en) | 2001-10-17 | 2002-10-17 | Method of reducing type 2 diabetes in high risk patients |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1438043A2 (es) |
JP (1) | JP2005531492A (es) |
AU (1) | AU2002335843A1 (es) |
CA (1) | CA2463682A1 (es) |
IL (1) | IL161388A0 (es) |
MX (1) | MXPA04003022A (es) |
WO (2) | WO2003032965A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2458288A1 (en) * | 2003-03-11 | 2004-09-11 | Institut De Cardiologie De Montreal / Montreal Heart Institute | Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure |
WO2005020984A2 (en) * | 2003-08-29 | 2005-03-10 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
WO2008025450A1 (en) * | 2006-08-28 | 2008-03-06 | Sanofi-Aventis Deutschland Gmbh | Methods of lowering glucose levels |
CN108785265A (zh) | 2013-03-14 | 2018-11-13 | 美国安进公司 | 杂环化合物和其用途 |
BR112015032410B8 (pt) * | 2013-06-26 | 2021-10-26 | Dong A St Co Ltd | Uso de uma composição farmacêutica compreendendo inibidores de dpp-iv no preparo de um medicamento para prevenção ou tratamento de doenças renais |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331014A3 (de) * | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe |
DE4308504A1 (de) * | 1993-03-18 | 1994-09-22 | Knoll Ag | Neue Verwendung einer Kombination aus Verapamil und Trandolapril |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
EE05670B1 (et) * | 1999-08-30 | 2013-08-15 | Aventis Pharma Deutschland Gmbh | Ramipriil kardiovaskulaarsete haigusjuhtude rahoidmiseks |
-
2002
- 2002-10-17 AU AU2002335843A patent/AU2002335843A1/en not_active Abandoned
- 2002-10-17 CA CA002463682A patent/CA2463682A1/en not_active Abandoned
- 2002-10-17 IL IL16138802A patent/IL161388A0/xx unknown
- 2002-10-17 WO PCT/US2002/033213 patent/WO2003032965A2/en not_active Application Discontinuation
- 2002-10-17 MX MXPA04003022A patent/MXPA04003022A/es unknown
- 2002-10-17 JP JP2003535767A patent/JP2005531492A/ja not_active Withdrawn
- 2002-10-17 WO PCT/EP2002/011636 patent/WO2003032963A2/en not_active Application Discontinuation
- 2002-10-17 EP EP02790295A patent/EP1438043A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO03032963A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2463682A1 (en) | 2003-04-24 |
AU2002335843A1 (en) | 2003-04-28 |
JP2005531492A (ja) | 2005-10-20 |
WO2003032963A2 (en) | 2003-04-24 |
IL161388A0 (en) | 2004-09-27 |
WO2003032965A2 (en) | 2003-04-24 |
WO2003032965A3 (en) | 2003-11-27 |
WO2003032963A3 (en) | 2003-12-24 |
MXPA04003022A (es) | 2004-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2378018C2 (ru) | Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности | |
AU2009200746B8 (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events | |
CA2904447C (en) | Therapy for complications of diabetes | |
ZA200503542B (en) | Pharmaceutical combination of telmisartan and atovastatin for the prophylaxis of treatment of cardiovascular, cardiopulmonary, pulmanory or renal diseases | |
TWI539949B (zh) | 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑 | |
WO1994028924A1 (en) | Combination of angiotensin converting enzyme inhibitors and aii antagonists | |
CN102076337A (zh) | 决奈达隆的单独或组合在制备用于治疗具有心律失常并具有肌酸酐水平升高的患者的药物中的用途 | |
WO2003032963A2 (en) | Method of reducing type 2 diabetes in high risk patients | |
EP0808172B1 (en) | Combination of angiotensin converting enzyme inhibitor and aldosterone antagonist for the treatment of ventricular hypertrophy | |
US20050065203A1 (en) | Method of reducing type 2 diabetes in high risk patients | |
CA3134786A1 (en) | Methods for treating subjects with chronic kidney disease | |
Fricker et al. | Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects | |
AU2002362897A1 (en) | Method of reducing type 2 diabetes in high risk patients | |
Fatourechi et al. | A practical guideline for management of hypertension in patients with diabetes | |
EP1414421B1 (en) | The treatment of lipodystrophy with inhibitors of the renin angiotensin system | |
AU2002319535A1 (en) | The treatment of lipodystrophy | |
Giles et al. | An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20040624 |
|
17Q | First examination report despatched |
Effective date: 20040811 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH |
|
18D | Application deemed to be withdrawn |
Effective date: 20050422 |